260 results about "Allergic asthma" patented technology

The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

The invention relates to compounds of general formula (I):

wherein R¹, R², R³, R⁴ and R⁵ are as defined herein

for the treatment of allergic conditions, wherein the treatment is by pulsed therapy which comprises a first period during which the compound is administered to the patient and a second period of at least seven days during which the compound is administered to the patient in a reduced amount. The invention also relates to compounds of general formula (I) for desensitizing the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis, or atopic dermatitis.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The invention discloses a Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and a preparation method thereof. The Chinese medicinal preparation comprises the following main raw material medicaments in part by weight: 4 to 36 parts of bupleurum, 5 to 30 parts of root of red-rooted salvia, 4 to 28 parts of paniculate swallowwort root, 4 to 28 parts of cicada slough, 6 to 32 parts of dry rehmannia root and 4 to 28 parts of ligusticum sinense oliver. The preparation method comprises the following steps of: 1, cleaning the medicinal materials with water; 2, drying the medicinal materials, crushing into medicinal powder of 100 to 200 meshes, uniformly mixing, soaking, decocting twice, filtering out, and mixing to obtain an active extract; when filtrate becomes thick paste with the concentration density of between 1.30 and 1.35, drying, and crushing into medicinal powder of 100 to 200 meshes to obtain powder; and 3, adding auxiliary materials, and preparing into capsules, tablets and the like. The Chinese medicinal preparation has the effects of resisting inflammation, resisting allergy and improving microcirculation, improves allergic body diathesis, improves resisting capability of a human body to allergens, and has obvious effects on the allergic rhinitis, the allergic asthma and the urticaria, short treatment cycle and low recurrence rate.

The invention provides an artemisia pollen allergen vaccine, and a preparation method and application thereof. The artemisia pollen allergen vaccine comprises an artemisia sieversiana pollen allergen, an artemisia annua pollen allergen and an artemisia argyi pollen allergen. Compared with a single artemisia pollen allergen vaccine, the combined vaccine has the advantages that the effectiveness of treatment is improved while the safety can be ensured; and the artemisia pollen allergen vaccine can be used for treating allergic dermatitis, chronic urticaria, allergic rhinitis and allergic asthma which are caused by allergy to multiple artemisia pollens.

The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.

The invention belongs to the technical field of biology, and relates to an allergic asthma model, in particular to application of chitosan serving as immuno-adjuvant in preparing a mouse allergic asthma model. According to the application, the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is subjected to airway responsiveness, lung tissue pathological examination and inflammation marker inspection, and results indicate that the mouse allergic asthma model prepared by applying chitosan serving as immuno-adjuvant is remarkably superior to a conventional immuno-adjuvant prepared asthma model in airway eosinophilic inflammation, airway responsiveness and airway inflammatory cytolines and other aspects. The chitosan has low price and rich sources; and the mouse asthma model by using chitosan as immuno-adjuvant is remarkably superior to a traditional adjuvant, and has the advantages of simple method, low cost, good reproducibility and the like.

The present invention relates to method of preparing dust mite allergen vaccine with nanometer particle as carrier. Dust mite is one of the main allergen causing allergic diseases. The present invention applies biodegradable nanometer PLGA particle as the allergen carrier to coat recombinant dust mite allergen Der p2/Der f2 in preparing nanometer level dust mite allergen vaccine. Specifically, by means of gene engineering technology, recombinant Der p2/Der f2 protein is prepared through cloning and expression in colibacillus and PLGA coated nanometer particle is prepared through re-emulsifying and solvent volatizing process. The form, average size, coating rate, medicine carrying amount and extracorporeal accumulation and release curve of the nanometer particle are obtained, and test shows that Der p2/Der f2-PLGA nanometer particle has certain curative effect on allergic asthma.

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

The invention discloses a closed bacterium polysaccharide and a preparing method; application of preparing cure allergic rhinitis medicine through closed bacterium polysaccharide and allergic asthma medicine and application of preparing cure adult respiratory distress syndrome medicine; which is characterized by the following parts: (1) the component of closed bacterium polysaccharide are more definite and the action of inhibit sensitized big rat antigen attack back lung acidophilia inflammation and can be developed to new medicine or functional food or health products be used to treat allergic rhinitis and allergic asthma; (2) the polysaccharides through PEG deposition polysaccharides to produce the closed bacterium polysaccharides are much more higher than polysaccharides preparing through alcohol deposition; and quantity of PEG is about one twentieth of alcohol.

The invention relates to a compound composition containing intal and statins claritin. The compound composition consists of the following components: a) a certain amount of intal; b) a certain amount of one of olopatadine hydrochloride, ioratadine, desloratadine, degreasing ioratadine, desloratadine, rupatadine and betahistine; c) other medicinal excipients. The compound composition can be made into external preparations such as eye drops, nose drops, aerosol, spray, inhalant, gelata, eye ointments, ointments or patch and the like. The compound composition can be used for curing the diseases such as anaphylactic eye diseases, anaphylactic rhinitis, skin urtication, urticaria, allergic asthma and the like, can significantly improve allergic symptoms, and has the characteristics of high efficiency, stability, safety, low adverse reaction rate, convenient use and the like.

The invention discloses a loratadine oral quickly-soluble film and a preparation method thereof. By controlling parameters such as particle size of a loratadine drug, proportion of a film-forming material, content of water of a film product and the like, the product dissolution is improved, the bioavailability can be improved, the preparation can effectively prevent and cure such as allergic rhinitis, chronic idiopathic urticaria, allergic asthma, atopic dermatitis and associated symptoms caused by allergy such as skin diseases (eczema, dermatitis, pruritus cutanea), and the drug effect can be sufficiently realized. The loratadine oral quickly-soluble film does not need water, can be rapidly dissolved in the oral cavity and is convenient to take by patients and particularly suitable for the old people and children patients; moreover, the loratadine oral quickly-soluble film has characteristics of high dispersity, rapidness in absorption, fastness in effect, favorability for improving the bioavailability, and the like.

The invention relates to an application to preparing a medicine for treating a disease caused by immunity imbalance of a mammal with a tumulosic acid compound K2-1 or other pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease caused by immunity imbalance is allergy, and the allergy is allergic asthma; and the tumulosic acid compound K2-1 is of a structure represented by a chemical formula shown in the specification, wherein R2=OH.

The invention discloses a vaccine for preventing and/or treating allergic asthma. The active ingredients of the vaccine for preventing and/or treating allelgic asthma is as the following: the compound consisting the proteantigen causing allergic asthma or epitope peptides and the recombinant eukaryotic cell expression carrier which inserts proteantigen causing allergic asthma or epitope peptides coding gene thereof in the multiple cloning site. The vaccine can induce to produce immune regulatory T cell, can restrain the activity of allergic T cell of immune animals, thus preventing and/or treating allergic asthma effectively.